I joined D Young & Co as a partner in 2020 after 14 years working as a biotechnology and life sciences patent attorney. My practice encompasses a wide range of technologies within the biotechnology and life science sectors and I feel particularly passionate when I can become fully involved in a client’s portfolio as this allows me to make a real difference to their business.

Prior to joining the firm I had been working elsewhere in private practice, at both large top tier firms and a small boutique practice. These previous appointments mean I have a wide range of experience in terms of technology area and client type, and have been exposed to a broad spectrum of patent issues.

My practice focusses on the fields of immunology, molecular biology, biotechnology and biochemistry. I also work on cross-sector patenting strategies relating to biotechnology and computational technologies (techbio). Within these fields I draft patent applications, prosecute patent applications before the EPO and UKIPO, handle oppositions and appeals at the EPO, and coordinate worldwide patent portfolios and European SPC portfolios. I have experience working with clients of all sizes, including single inventors, universities, small start-ups and large multi-nationals.

I am a regular speaker at both biotech industry and patent events on topics including antibody patenting and the availability of second medical use claims. As a member of the BioIndustry Association’s (BIA) Cell and Gene Therapy Advisory Committee I regularly advise firms working in this area on patent issues, ranging from the potential implications of the Unitary Patent Convention (UPC), the implications of Brexit on IP and the GMO Directive.

I have signed the IP Inclusive Senior Leaders' Pledge to demonstrate my personal commitment to improving diversity and inclusion (D&I) in our firm.

Awards

Recognised as a recommended individual by IAM Patent 1000 2024.

Publications

• European Biotechnology Review (2018), Patentability of Biosimilars.
• Practical Law (2017), Analysis and Impact of Actavis v Lilly.